文献速递浆细胞疾病

硼替佐米、美法仑和泼尼松诱导后以来那度胺和地塞米松维持对比卡非佐米、来那度胺和地塞米松联合或不联合达雷妥尤单抗治疗老年适合的新诊断多发性骨髓瘤(GEM-2017FIT):一项3期、开放标签、多中心、随机临床试验

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.
PubMed 文献 · Lancet Haematol · 2025-01-01

GEM-2017FIT研究在西班牙57家医院纳入65-80岁新诊断多发性骨髓瘤患者,随机分配至VMP9-Rd9、KRd或D-KRd组。主要终点诱导后MRD阴性率在KRd组和D-KRd组均高于VMP9-Rd9组。D-KRd组毒性相关死亡频率较高。

要点

  • KRd和D-KRd方案在18周期后MRD阴性率优于VMP9-Rd9方案。
  • KRd组3-4级中性粒细胞减少发生率低于VMP9-Rd9组和D-KRd组。
  • D-KRd组毒性相关死亡频率显著高于VMP9-Rd9组和KRd组。

核心结论

  • KRd和D-KRd在18周期后达到MRD阴性方面优于VMP9-Rd9。
  • 本研究可能有助于将四联疗法纳入临床实践,并支持在治疗选择中进行基于衰弱评估的必要性。

研究设计与样本

  • GEM-2017FIT是一项在西班牙57家医院进行的开放标签、随机、3期试验。
  • 纳入65-80岁患者,使用GAH量表评估衰弱,随机分配(1:1:1)至VMP9-Rd9(n=154)、KRd(n=154)或D-KRd(n=154,其中1例随后发现不符合条件)。
  • 所有完成诱导和巩固治疗的患者根据MRD状态分层,随后随机分配(1:1)至达雷妥尤单抗联合来那度胺维持治疗或无维持治疗。
  • 主要终点为诱导后MRD阴性,在意向治疗人群中评估。
  • 试验注册于ClinicalTrials.gov,NCT03742297。

主要发现

  • 2018年10月15日至2021年12月15日,540例患者入组并评估资格,462例符合条件并随机分配。
  • 461例患者中230例(50%)为男性,231例(50%)为女性。
  • 中位随访33.15个月(IQR 25.82-43.08)。
  • 18周期后灵敏度10^-5的不可检测MRD率:KRd组83/154(54%),OR 1.73(95% CI 1.39-2.16),p<0.0001;D-KRd组94/153(61%),OR 2.03(95% CI 1.61-2.57),p<0.0001;VMP9-Rd9组41/154(27%)。
  • 3-4级中性粒细胞减少发生率:KRd组37/154(24%),VMP9-Rd9组62/154(40%),D-KRd组63/153(41%)。

关键数值与推荐

  • 主要终点:18周期后意向治疗人群中灵敏度10^-5的不可检测MRD率,KRd组54% vs VMP9-Rd9组27%(OR 1.73,95% CI 1.39-2.16;p<0.0001),D-KRd组61% vs VMP9-Rd9组27%(OR 2.03,95% CI 1.61-2.57;p<0.0001)。
  • 3-4级中性粒细胞减少:KRd组24% vs VMP9-Rd9组40% vs D-KRd组41%。
  • 3-4级感染:VMP9-Rd9组12% vs KRd组15% vs D-KRd组16%。
  • 毒性相关死亡:VMP9-Rd9组5% vs KRd组3% vs D-KRd组8%(OR 0.53,95% CI 0.22-1.30;p=0.16)。

临床怎么用

  • KRd和D-KRd在18周期后MRD阴性方面优于VMP9-Rd9。
  • 本研究可能有助于将四联疗法纳入临床实践,并支持在治疗选择中进行基于衰弱评估的必要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triplet and quadruplet regimens based on bortezomib, melphalan and prednisone (VMP) and lenalidomide and dexamethasone (Rd) with anti-CD38 antibodies are potential treatments for transplant-ineligible patients with newly diagnosed multiple myeloma. However, the high risk of toxic effects in this population requires frailty-based therapy adaptation. We aimed to compare the response of carfilzomib-based triplet and quadruplet regimens with a VMP-Rd regimen in newly diagnosed transplant-ineligible patients with multiple myeloma, considering patient frailty. METHODS: GEM-2017FIT was an open-label, randomised, phase 3 trial at 57 hospitals in Spain. Patients aged 65-80 years were enrolled and assessed for frailty using the Geriatric Assessment in Hematology (GAH) scale. Patients were randomly assigned (1:1:1) to receive 18-cycle induction therapy of VMP 9-Rd 9 (one six-week cycle of melphalan 9 mg/m2 and prednisone 60 mg/m2 on days 1-4; bortezomib 1·3 mg/m2 subcutaneous twice weekly, followed by eight four-week cycles of weekly VMP and nine four-week cycles of lenalidomide 25 mg on days 1-21 and dexamethasone 40 mg weekly), carfilzomib-based triplet (KRd; carfilzomib intravenously 20 mg/m2 [only in the infusion on day 1 in first cycle] or 36 mg/m2 on days 1, 2, 8, 9, 15, and 16 in cycles 1-2, 56 mg/m2 in cycles 3-18, plus Rd) or daratumumab-KRd (D-KRd; daratumumab 16 mg/kg intravenous weekly [cycles 1-2], biweekly [cycles 3-6], and every 4 weeks [cycles 7-18]). All patients who completed induction therapy and consolidation were stratified by measurable residual disease status and both those with undetectable measurable residual disease and detectable measurable residual disease were subsequently randomly assigned (1:1) to maintenance therapy with daratumumab and lenalidomide or no maintenance therapy. The primary endpoint was measurable residual disease negativity after induction, which was assessed in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT03742297. FINDINGS: Between October 15, 2018 and December 15, 2021, 540 patients were enrolled and assessed for eligibility. 462 were eligible for the study and randomly assigned to VMP 9-Rd 9 (n=154), KRd (n=154) or D-KRd (n=154, with one patient subsequently found to be ineligible). 230 (50%) of 461 patients were male and 231 (50%) were female. Patients were followed up for a median of 33·15 months (IQR 25·82-43·08). The 18-cycle undetectable measurable residual disease rate with a sensitivity level of 10-5 in the intention-to-treat population was higher in the KRd group (83 [54%] of 154 patients; odds ratio [OR] 1·73, 95% CI 1·39-2·16; p<0·0001) and D-KRd group (94 [61%] of 153 patients; 2·03, 1·61-2·57; p<0·0001) than in the VMP 9-Rd 9 group (41 [27%] of 154 patients). The incidence of grade 3-4 neutropenia was lower in the KRd group (37 [24%] of 154 patients) compared with the VMP 9-Rd 9 group (62 [40%] of 154 patients) and D-KRd group (63 [41%] of 153 patients). Grade 3-4 infections occurred in 19 (12%) patients in the VMP 9-Rd 9 group, 23 (15%) patients in the KRd group, and 25 (16%) patients in the D-KRd group. Toxicity-related death occurred in a similar frequency in the VMP 9-Rd 9 (seven [5%] patients) and KRd (five [3%] patients) groups, but was significantly higher in the D-KRd group (13 [8%] patients; OR 0·53, 95% CI 0·22-1·30; p=0·16). INTERPRETATION: KRd and D-KRd were superior to VMP 9-Rd 9 in achieving measurable residual disease negativity after 18 cycles. This study could contribute to incorporation of quadruplet therapy into clinical practice and supports the need for frailty-based assessment in therapy selection. FUNDING: PETHEMA.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Mateos MV, Paiva B, Cedena MT, et al. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial. Lancet Haematol. 2025. PMID: 40769684. doi:10.1016/S2352-3026(25)00143-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。